Skip to main content

Share story

Science

Starlink 17-18 Adds 25 Satellites to 9931-Strong Constellation

Starlink 17-18 Adds 25 Satellites to 9931-Strong Constellation Image: Primary
SpaceX launched 25 Starlink satellites on March 6, 2026, aboard a Falcon 9 rocket from Vandenberg Space Force Base. The liftoff took place from pad 4E during a window opening at 14:33:30 UTC. The mission, designated Starlink 17-18, placed the payload into low Earth orbit as part of Shell 17. The deployment adds to a constellation that now totals 11,463 satellites launched. Of those, 9,931 are in orbit and 9,920 are actively working. The newly deployed satellites are expected to complete phasing maneuvers and reach operational altitude within the coming weeks. The Falcon 9 booster is expected to return to a drone ship or landing zone for recovery. The satellites will undergo on-orbit checkouts before joining the existing fleet serving residential, maritime, and government customers.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from KeepTrack and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.